Allergy vaccination for people with dog allergy, including allergic rhinitis and asthma
Tests Alutard SQ Dog allergy treatment in adults with moderate-to-severe dog allergy.
Plain-language title generated from the registry record
Registry title: Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice
Key facts
- Where
- Lund and Trelleborg, SwedenSee the 2 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07651891, who can take part
Where in Sweden
- Lund University HospitalLund, SwedenTaking people
- Trelleborg HospitalTrelleborg, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska Institutet
- Trial code
- NCT07651891
- Record updated
- 29 June 2026
- Original description
STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls.Read full original descriptionShow less
Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice
STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls.
STUDY OUTLINE
The study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected.
Following the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline.
Allergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.
Inclusion: The subject has provided written informed consent to participate in the study; Age 18-50 years; Moderate-to-severe allergic symptoms upon exposure to dogs; Dog allergy confirmed by positive specific IgE; Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC); Female subjects of childbearing potential must use adequate contraception; A negative pregnancy test must be obtained prior to enrolment.
Exclusion: Treatment with medications that may interfere with the immune response; Previous immunotherapy or chemotherapy; Autoimmune or connective tissue disease; Cardiovascular disease; Hepatic disease; Renal disease; Malignancy; Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis); Chronic obstructive or restrictive lung disease; Significant chronic disease; Major metabolic disease; Known or suspected hypersensitivity to the study product; Suspected or confirmed bacterial infection; Clinically relevant allergy to house dust mite; Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate; Pregnancy or breastfeeding; Alcohol or substance abuse; Mental or cognitive incapacity that may impair compliance with study procedures; Current dog ownership; Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.